Dec 2 (Reuters) - Critical Outcome Technologies Inc COT.V :
* Pursues orphan drug designation for COTI-2 intended to treat Li-Fraumeni
Syndrome
* Orphan drug designation may result in COTI-2 being directed down a unique
development pathway within the FDA
* Says foresee commencing the Phase 1 clinical trial of COTI-2 in mid-December
* Source text for Eikon ID:nMKWQv29da
* Further company coverage COT.V